超声心排血量监测仪与连续温度稀释法测量心排血量和心排血指数的比较研究

目的 评价连续波多普勒超声心排血量监测仪(USCOMlA)和连续温度稀释心排血量监测仪(VIGILANCElA)监测冠状动脉旁路移植术(CABG)后患者的心排血量(CO)和心排血指数(CI),检验USCOMlA监测CO、CI的准确性.方法 利用USCOMlA和VIGILANCElA双盲监测18例CAB(;后患者的CO、CI,并分析其相关性.结果 USCOMlA和VIGILANCElA监测的CO、CI相关性良好(rco=0.785,P<0.01;m=0.727,P<0.01).结论 可用无创的USCOMlA取代有创的VIGILANCE1A测量CO.     

超声心排血量监测仪与连续温度稀释法测量心排血量和心排血指数的比较研究

目的 评价连续波多普勒超声心排血量监测仪(USCOMlA)和连续温度稀释心排血量监测仪(VIGILANCElA)监测冠状动脉旁路移植术(CABG)后患者的心排血量(CO)和心排血指数(CI),检验USCOMlA监测CO、CI的准确性.方法 利用USCOMlA和VIGILANCElA双盲监测18例CAB(;后患者的CO、CI,并分析其相关性.结果 USCOMlA和VIGILANCElA监测的CO、CI相关性良好(rco=0.785,P<0.01;m=0.727,P<0.01).结论 可用无创的USCOMlA取代有创的VIGILANCE1A测量CO.     

超声心排血量监测仪与连续温度稀释法测量心排血量和心排血指数的比较研究

目的 评价连续波多普勒超声心排血量监测仪(USCOMlA)和连续温度稀释心排血量监测仪(VIGILANCElA)监测冠状动脉旁路移植术(CABG)后患者的心排血量(CO)和心排血指数(CI),检验USCOMlA监测CO、CI的准确性.方法 利用USCOMlA和VIGILANCElA双盲监测18例CAB(;后患者的CO、CI,并分析其相关性.结果 USCOMlA和VIGILANCElA监测的CO、CI相关性良好(rco=0.785,P<0.01;m=0.727,P<0.01).结论 可用无创的USCOMlA取代有创的VIGILANCE1A测量CO.     

超声心排血量监测仪与连续温度稀释法测量心排血量和心排血指数的比较研究

目的 评价连续波多普勒超声心排血量监测仪(USCOMlA)和连续温度稀释心排血量监测仪(VIGILANCElA)监测冠状动脉旁路移植术(CABG)后患者的心排血量(CO)和心排血指数(CI),检验USCOMlA监测CO、CI的准确性.方法 利用USCOMlA和VIGILANCElA双盲监测18例CAB(;后患者的CO、CI,并分析其相关性.结果 USCOMlA和VIGILANCElA监测的CO、CI相关性良好(rco=0.785,P<0.01;m=0.727,P<0.01).结论 可用无创的USCOMlA取代有创的VIGILANCE1A测量CO.     

超声心排血量监测仪与连续温度稀释法测量心排血量和心排血指数的比较研究

目的 评价连续波多普勒超声心排血量监测仪(USCOMlA)和连续温度稀释心排血量监测仪(VIGILANCElA)监测冠状动脉旁路移植术(CABG)后患者的心排血量(CO)和心排血指数(CI),检验USCOMlA监测CO、CI的准确性.方法 利用USCOMlA和VIGILANCElA双盲监测18例CAB(;后患者的CO、CI,并分析其相关性.结果 USCOMlA和VIGILANCElA监测的CO、CI相关性良好(rco=0.785,P<0.01;m=0.727,P<0.01).结论 可用无创的USCOMlA取代有创的VIGILANCE1A测量CO.     

超声心排血量监测仪与连续温度稀释法测量心排血量和心排血指数的比较研究

目的 评价连续波多普勒超声心排血量监测仪(USCOMlA)和连续温度稀释心排血量监测仪(VIGILANCElA)监测冠状动脉旁路移植术(CABG)后患者的心排血量(CO)和心排血指数(CI),检验USCOMlA监测CO、CI的准确性.方法 利用USCOMlA和VIGILANCElA双盲监测18例CAB(;后患者的CO、CI,并分析其相关性.结果 USCOMlA和VIGILANCElA监测的CO、CI相关性良好(rco=0.785,P<0.01;m=0.727,P<0.01).结论 可用无创的USCOMlA取代有创的VIGILANCE1A测量CO.     

超声心排血量监测仪与连续温度稀释法测量心排血量和心排血指数的比较研究

目的 评价连续波多普勒超声心排血量监测仪(USCOMlA)和连续温度稀释心排血量监测仪(VIGILANCElA)监测冠状动脉旁路移植术(CABG)后患者的心排血量(CO)和心排血指数(CI),检验USCOMlA监测CO、CI的准确性.方法 利用USCOMlA和VIGILANCElA双盲监测18例CAB(;后患者的CO、CI,并分析其相关性.结果 USCOMlA和VIGILANCElA监测的CO、CI相关性良好(rco=0.785,P<0.01;m=0.727,P<0.01).结论 可用无创的USCOMlA取代有创的VIGILANCE1A测量CO.     

超声心排血量监测仪与连续温度稀释法测量心排血量和心排血指数的比较研究

目的 评价连续波多普勒超声心排血量监测仪(USCOMlA)和连续温度稀释心排血量监测仪(VIGILANCElA)监测冠状动脉旁路移植术(CABG)后患者的心排血量(CO)和心排血指数(CI),检验USCOMlA监测CO、CI的准确性.方法 利用USCOMlA和VIGILANCElA双盲监测18例CAB(;后患者的CO、CI,并分析其相关性.结果 USCOMlA和VIGILANCElA监测的CO、CI相关性良好(rco=0.785,P<0.01;m=0.727,P<0.01).结论 可用无创的USCOMlA取代有创的VIGILANCE1A测量CO.     

超声心排血量监测仪与连续温度稀释法测量心排血量和心排血指数的比较研究

目的 评价连续波多普勒超声心排血量监测仪(USCOMlA)和连续温度稀释心排血量监测仪(VIGILANCElA)监测冠状动脉旁路移植术(CABG)后患者的心排血量(CO)和心排血指数(CI),检验USCOMlA监测CO、CI的准确性.方法 利用USCOMlA和VIGILANCElA双盲监测18例CAB(;后患者的CO、CI,并分析其相关性.结果 USCOMlA和VIGILANCElA监测的CO、CI相关性良好(rco=0.785,P<0.01;m=0.727,P<0.01).结论 可用无创的USCOMlA取代有创的VIGILANCE1A测量CO.     

超声心排血量监测仪与连续温度稀释法测量心排血量和心排血指数的比较研究

目的 评价连续波多普勒超声心排血量监测仪(USCOMlA)和连续温度稀释心排血量监测仪(VIGILANCElA)监测冠状动脉旁路移植术(CABG)后患者的心排血量(CO)和心排血指数(CI),检验USCOMlA监测CO、CI的准确性.方法 利用USCOMlA和VIGILANCElA双盲监测18例CAB(;后患者的CO、CI,并分析其相关性.结果 USCOMlA和VIGILANCElA监测的CO、CI相关性良好(rco=0.785,P<0.01;m=0.727,P<0.01).结论 可用无创的USCOMlA取代有创的VIGILANCE1A测量CO.     

A cardiac arrest policy

The following article describes the process in the development and implementation of an Operating Room's Cardiac Arrest Policy. The actual guidelines and forms developed are presented.     

A personalised approach to cardiac rehabilitation

Patients' beliefs about their myocardial infarction will affect their physical and emotional recovery. An individualised, behavioural approach to rehabilitation aims to treat the patient as an adult learner who participates fully in negotiating priorities for rehabilitation. Initiating rehabilitation advice in the very early stages post-AMI requires the use of specific nursing interventions.     

A cardiac patch from aligned microvessel and cardiomyocyte patches

Cardiac tissue engineering aims to produce replacement tissue patches in the lab to replace or treat infarcted myocardium. However, current patches lack preformed microvascularization and are therefore limited in thickness and force production. In this study, we sought to assess whether a bilayer patch composed of a layer made from human induced pluripotent stem cell‐derived cardiomyocytes and a microvessel layer composed of self‐assembled human blood outgrowth endothelial cells and pericytes was capable of engrafting on the epicardial surface of a nude rat infarct model and becoming perfused by the host 4 weeks after acute implantation. The bilayer configuration was found to increase the twitch force production, improve human induced pluripotent stem cell‐derived cardiomyocyte survival and maturation, and increase patent microvessel lumens compared with time‐matched single layer controls after 2 weeks of in vitro culture. Upon implantation, the patch microvessels sprouted into the cardiomyocyte layer of the patch and inosculated with the host vasculature as evidenced by species‐specific perfusion labels and erythrocyte staining. Our results demonstrate that the added microvessel layer of a bilayer patch substantially improves in vitro functionality and that the bilayer patch is capable of engraftment with rapid microvessel inosculation on injured myocardium. The bilayer format will allow for scaling up in size through the addition of layers to obtain thicker tissues generating greater force in the future.